CN114671836A - A kind of synthetic method of amiodarone impurity C - Google Patents

A kind of synthetic method of amiodarone impurity C Download PDF

Info

Publication number
CN114671836A
CN114671836A CN202111660207.8A CN202111660207A CN114671836A CN 114671836 A CN114671836 A CN 114671836A CN 202111660207 A CN202111660207 A CN 202111660207A CN 114671836 A CN114671836 A CN 114671836A
Authority
CN
China
Prior art keywords
amiodarone
impurity
synthetic method
solvent
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111660207.8A
Other languages
Chinese (zh)
Other versions
CN114671836B (en
Inventor
王莹国
石庆然
陈阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Wangzhixing Pharmaceutical Technology Co ltd
Original Assignee
Nanjing Wangzhixing Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Wangzhixing Pharmaceutical Technology Co ltd filed Critical Nanjing Wangzhixing Pharmaceutical Technology Co ltd
Priority to CN202111660207.8A priority Critical patent/CN114671836B/en
Publication of CN114671836A publication Critical patent/CN114671836A/en
Application granted granted Critical
Publication of CN114671836B publication Critical patent/CN114671836B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明一种胺碘酮杂质C的合成方法,包括以下步骤:(1)将化合物Ⅰ溶于溶剂中,在碱的作用下,与N,N‑二乙基‑β‑氯乙胺盐酸盐进行取代反应得到中间体1;(2)中间体1溶于溶剂中,在碱的作用下,与碘单质反应得到胺碘酮杂质C;本发明操作简单,成本低廉,按照该方法合成的胺碘酮杂质C作为杂质对照品,为胺碘酮的质量控制提供了合格、低廉、易得的对照品,为胺碘酮药物的生产和安全用药提供了重要的指导意义。

Figure 202111660207

A method for synthesizing amiodarone impurity C of the present invention comprises the following steps: (1) dissolving compound I in a solvent, under the action of a base, mix with N,N-diethyl-β-chloroethylamine hydrochloride The salt is subjected to substitution reaction to obtain intermediate 1; (2) intermediate 1 is dissolved in a solvent, and under the action of a base, reacts with elemental iodine to obtain amiodarone impurity C; the present invention is simple in operation and low in cost, and is synthesized according to the method. Amiodarone impurity C, as an impurity reference substance, provides a qualified, low-cost and easy-to-obtain reference substance for the quality control of amiodarone, and provides important guiding significance for the production of amiodarone drugs and safe medication.

Figure 202111660207

Description

一种胺碘酮杂质C的合成方法A kind of synthetic method of amiodarone impurity C

技术领域technical field

本发明属于医药技术领域,具体涉及一种盐酸胺碘酮杂质C的制备方法。The invention belongs to the technical field of medicine, and in particular relates to a preparation method of amiodarone hydrochloride impurity C.

背景技术Background technique

胺碘酮(Amiodarone)又名乙胺碘呋酮,胺碘酮(或其盐酸盐CAS:19774-82-4)是一个广泛用 于治疗及预防室性及室上性心律失常的第三类抗心律失常药物。现代社会心血管疾病的患者 大幅攀升,对该类药物的需求量也日益增加。基于稳定的疗效和较低的副作用,盐酸胺碘酮 的市场份额不断扩大。相应的对胺碘酮杂质的研究及合成方法也进行了广泛的报道,发现目 前对胺碘酮欧洲药典EP杂质C合成方法进行报道的文献并不多。因此,找到一种操作简单, 成本低廉、容易分离提纯,收率高的胺碘酮杂质C的合成方法具有重要意义。特提出如下发 明:Amiodarone, also known as amiodarone, amiodarone (or its hydrochloride CAS: 19774-82-4) is a third drug widely used in the treatment and prevention of ventricular and supraventricular arrhythmias. Antiarrhythmic drugs. The number of patients with cardiovascular disease in modern society has risen sharply, and the demand for such drugs is also increasing. Based on stable efficacy and low side effects, the market share of amiodarone hydrochloride continues to expand. Correspondingly, the research and synthesis method of amiodarone impurity have also been widely reported, and it is found that there are not many documents that the amiodarone European Pharmacopoeia EP impurity C synthesis method is reported at present. Therefore, it is of great significance to find a synthesis method of amiodarone impurity C with simple operation, low cost, easy separation and purification, and high yield. The following inventions are hereby proposed:

盐酸胺碘酮,其结构式如下:Amiodarone hydrochloride, its structural formula is as follows:

Figure BDA0003446769720000011
Figure BDA0003446769720000011

盐酸胺碘酮杂质C结构式如下:Amiodarone hydrochloride impurity C structural formula is as follows:

Figure BDA0003446769720000012
Figure BDA0003446769720000012

Bioorganic & Medicinal Chemistry Letters 18(2008)5920–5922公开报道了一种合成胺碘 酮杂质C的方法如下:Bioorganic & Medicinal Chemistry Letters 18 (2008) 5920-5922 publicly reported a method for synthesizing amiodarone impurity C as follows:

Figure BDA0003446769720000021
Figure BDA0003446769720000021

第一步化合物I加入甲醇溶解,加入碘化钠和氢氧化钠,降温到-5℃滴加次氯酸钠,反 应完用稀盐酸淬灭反应,后处理提纯得到中间体1,收率25%,上两个碘的副产物收率11%。 第二步在碱的作用下对接N,N-二乙基-β-氯乙胺盐酸盐,反应得到目标产物。文献中第一步反 应收率偏低,杂质较多,而且生成中间体1和上两个碘副产物极性类似,分离提纯困难。因 此找到一种收率高、成本低、操作简单、容易分离提纯的方法进行合成胺碘酮杂质C是十分 必要的,对提高药物质量标准有重要意义。In the first step, compound I was dissolved in methanol, sodium iodide and sodium hydroxide were added, the temperature was lowered to -5 °C, and sodium hypochlorite was added dropwise. After the reaction was completed, the reaction was quenched with dilute hydrochloric acid. The yield of two iodine by-products was 11%. In the second step, N,N-diethyl-β-chloroethylamine hydrochloride is docked under the action of alkali, and the target product is obtained by the reaction. In the literature, the first step reaction yield is on the low side, impurities are many, and the polarities of the intermediate 1 and the upper two iodine by-products are similar, and separation and purification are difficult. Therefore it is very necessary to find a high yield, low cost, simple operation, easy separation and purification method to synthesize amiodarone impurity C, and it is of great significance to improve the drug quality standard.

发明内容SUMMARY OF THE INVENTION

为解决上述问题,本发明公开了一种,成本低、操作简单、收率高,易分离纯化的胺碘 酮杂质C的合成方法。In order to solve the above problems, the present invention discloses a kind of synthetic method of amiodarone impurity C with low cost, simple operation, high yield and easy separation and purification.

为达到上述目的,本发明的技术方案如下:For achieving the above object, technical scheme of the present invention is as follows:

一种胺碘酮杂质C的合成方法,包括以下步骤:A kind of synthetic method of amiodarone impurity C, comprises the following steps:

(1)将化合物Ⅰ溶于溶剂中,在碱的作用下,与N,N-二乙基-β-氯乙胺盐酸盐进行取代 反应得到中间体1;(1) compound I is dissolved in solvent, under the action of alkali, carry out substitution reaction with N,N-diethyl-β-chloroethylamine hydrochloride to obtain intermediate 1;

(2)中间体1溶于溶剂中,在碱的作用下,与碘单质反应得到胺碘酮杂质C。(2) Intermediate 1 is dissolved in a solvent and reacted with elemental iodine under the action of a base to obtain amiodarone impurity C.

胺碘酮杂质C的具体合成工艺路线如下:The concrete synthesis process route of amiodarone impurity C is as follows:

Figure BDA0003446769720000022
Figure BDA0003446769720000022

进一步地,步骤(1)中,所述化合物Ⅰ与N,N-二乙基-β-氯乙胺盐酸盐的摩尔比为1:1.0-4.0, 优选地,所述化合物Ⅰ与N,N-二乙基-β-氯乙胺盐酸盐的摩尔比为1:1.2。Further, in step (1), the molar ratio of the compound I to N,N-diethyl-β-chloroethylamine hydrochloride is 1:1.0-4.0, preferably, the compound I and N, The molar ratio of N-diethyl-β-chloroethylamine hydrochloride was 1:1.2.

进一步地,步骤(1)中,所述碱与化合物I的摩尔比为1.0-4.0:1.0,优选地,所述碱与 化合物I的摩尔比为2.0:1.0;所述溶剂与化合物I的体积比为1.0-100.0:1.0,优选地,所述溶 剂与化合物I的体积比为30.0:1.0。Further, in step (1), the molar ratio of the base to the compound I is 1.0-4.0:1.0, preferably, the molar ratio of the base to the compound I is 2.0:1.0; the volume of the solvent and the compound I The ratio is 1.0-100.0:1.0, preferably, the volume ratio of the solvent to compound I is 30.0:1.0.

进一步地,步骤(1)中,所述碱为碳酸钾、碳酸钠、碳酸铯、氢氧化钠、氢氧化钾、氢氧化锂中的一种或多种,优选地,所述碱为碳酸钾;所述溶剂为甲苯、水、乙腈、丙酮、四 氢呋喃、N,N-二甲基甲酰胺、二甲基亚砜中的一种或多种,优选地,所述溶剂为水和甲苯的 混合物。Further, in step (1), the alkali is one or more of potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, preferably, the alkali is potassium carbonate ; Described solvent is one or more in toluene, water, acetonitrile, acetone, tetrahydrofuran, N,N-dimethylformamide, dimethyl sulfoxide, preferably, described solvent is the mixture of water and toluene .

进一步地,步骤(1)中,所述取代反应的温度为30-90℃,优选地,所述取代反应的温 度为80-85℃,反应的时间为1-6小时,优选地,所述反应的时间为1小时。Further, in step (1), the temperature of the substitution reaction is 30-90°C, preferably, the temperature of the substitution reaction is 80-85°C, and the reaction time is 1-6 hours, preferably, the The reaction time was 1 hour.

进一步地,步骤(2)中,所述间体1与碘单质的摩尔比为1:0.5-3.0,优选地,所述中间 体与碘单质的摩尔比为1:0.9。Further, in step (2), the mol ratio of described intermediate 1 and iodine elemental substance is 1:0.5-3.0, preferably, the mol ratio of described intermediate and iodine elemental substance is 1:0.9.

进一步地,步骤(2)中,所述碱与中间体1的摩尔比为1.0-5.0:1.0,优选地,所述碱与 中间体1的摩尔比为1.0:1.0;所述溶剂与中间体1的体积比为1.0-100.0:1.0,优选地,所述溶 剂与中间体1的体积比为20.0:1.0。Further, in step (2), the molar ratio of the base to the intermediate 1 is 1.0-5.0:1.0, preferably, the molar ratio of the base to the intermediate 1 is 1.0:1.0; the solvent and the intermediate The volume ratio of 1 is 1.0-100.0:1.0, preferably, the volume ratio of the solvent to the intermediate 1 is 20.0:1.0.

进一步地,步骤(2)中,所述碱为碳酸钾、碳酸钠、碳酸铯、氢氧化钠、氢氧化钾、氢氧化锂中的一种或多种,优选地,所述碱为氢氧化钠;所述溶剂为甲醇、乙醇、异丙醇、丙酮、乙腈、四氢呋喃、乙酸乙酯中的一种或多种,优选地,所述溶剂为甲醇。Further, in step (2), the alkali is one or more of potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, preferably, the alkali is hydroxide sodium; the solvent is one or more of methanol, ethanol, isopropanol, acetone, acetonitrile, tetrahydrofuran, and ethyl acetate, preferably, the solvent is methanol.

进一步地,步骤(2)中,所述反应的温度为0-30℃,优选地,所述反应的温度为0-5℃; 反应的时间为2-12小时,优选地,所述反应的时间为6小时。Further, in step (2), the temperature of the reaction is 0-30°C, preferably, the temperature of the reaction is 0-5°C; the reaction time is 2-12 hours, preferably, the reaction time is 2-12 hours. The time is 6 hours.

本发明的有益效果为:The beneficial effects of the present invention are:

本发明胺碘酮杂质C的合成方法,改变了原报道文献中先上碘,然后再对接N,N-二乙基 -β-氯乙胺盐酸盐的合成路线,改为先对接N,N-二乙基-β-氯乙胺盐酸盐,然后再低温下和碘单 质反应上碘。本方法收率高,操作简单、成本低廉,容易分离提纯。为盐酸胺碘酮质量控制 提供了一种合格,低成本的杂质对照品。The synthetic method of amiodarone impurity C of the present invention changes the synthetic route of first adding iodine and then docking N,N-diethyl-β-chloroethylamine hydrochloride in the original report document, and changing to first docking N, N-diethyl-β-chloroethylamine hydrochloride, and then react with iodine at low temperature to add iodine. The method has the advantages of high yield, simple operation, low cost and easy separation and purification. A qualified and low-cost impurity reference substance is provided for the quality control of amiodarone hydrochloride.

附图说明Description of drawings

图1为本发明实施例4所得产物的核磁氢谱图;Fig. 1 is the hydrogen nuclear magnetic spectrum of the product obtained in Example 4 of the present invention;

图2为本发明实施例4所得产物的质谱谱图;Fig. 2 is the mass spectrogram of the product obtained in Example 4 of the present invention;

图3为本发明实施例4所得产物的HPLC谱图;Fig. 3 is the HPLC spectrogram of the product obtained in Example 4 of the present invention;

图4为本发明合成工艺路线。Fig. 4 is the synthetic process route of the present invention.

具体实施方式Detailed ways

下面结合附图和具体实施方式,进一步阐明本发明,应理解下述具体实施方式仅用于说 明本发明而不用于限制本发明的范围。Below in conjunction with the accompanying drawings and specific embodiments, the present invention will be further explained, and it should be understood that the following specific embodiments are only used to illustrate the present invention and not to limit the scope of the present invention.

实施例1Example 1

在500ml三口瓶中,加入10.0g(0.034mol)化合物I,加100ml水和200ml甲苯;加入9.4g(0.068mol)碳酸钾,体系呈浑浊白色,升温到50-55℃,分批加入7.0g(0.041mol)N,N-二乙 基-β-氯乙胺盐酸盐,过程中体系渐溶清。升温到80-85℃反应1小时。TLC检测反应完全, 反应液降温,加入50ml水,分层分出有机相,水相加100ml*2乙酸乙酯萃取,合并有机相加 50ml饱和食盐水洗涤,加入20g无水硫酸钠干燥,过滤除去盐,浓缩除去溶剂;经柱层析(纯 EA)得到11.5g中间体1,收率85%,HPLC纯度95%。In a 500ml three-necked flask, add 10.0g (0.034mol) of compound I, add 100ml of water and 200ml of toluene; add 9.4g (0.068mol) of potassium carbonate, the system is cloudy white, heat up to 50-55°C, add 7.0g in batches (0.041mol) N,N-diethyl-β-chloroethylamine hydrochloride, the system gradually dissolved and cleared during the process. The temperature was raised to 80-85°C for 1 hour. TLC detected that the reaction was complete, the reaction solution was cooled, 50 ml of water was added, the organic phase was separated by layers, the aqueous phase was extracted with 100 ml*2 ethyl acetate, the combined organic phases were washed with 50 ml of saturated brine, dried by adding 20 g of anhydrous sodium sulfate, and filtered. The salt was removed, and the solvent was removed by concentration; 11.5 g of intermediate 1 was obtained by column chromatography (pure EA), the yield was 85%, and the HPLC purity was 95%.

实施例2Example 2

在500ml三口瓶中,加入10.0g(0.034mol)化合物I,加100ml丙酮;加入1.4g(0.034mol) 氢氧化钠,体系呈浑浊白色,升温到50-55℃,分批加入11.7g(0.068mol)N,N-二乙基-β-氯乙 胺盐酸盐,过程中体系渐溶清。升温到80-85℃反应1.5小时。TLC检测反应完全,反应液降 温,加入50ml水,分层分出有机相,水相加100ml*2乙酸乙酯萃取,合并有机相加50ml饱 和食盐水洗涤,加入20g无水硫酸钠干燥,过滤除去盐,浓缩除去溶剂;经柱层析(纯EA) 得到10.7g中间体1,收率79.9%,HPLC纯度94%。In a 500ml three-necked flask, add 10.0g (0.034mol) of compound I, add 100ml of acetone; add 1.4g (0.034mol) of sodium hydroxide, the system is cloudy white, heat up to 50-55°C, add 11.7g (0.068g) in batches mol)N,N-diethyl-β-chloroethylamine hydrochloride, the system gradually dissolves and clears during the process. The temperature was raised to 80-85°C for 1.5 hours. TLC detected that the reaction was complete, the reaction solution was cooled, 50ml of water was added, the organic phase was separated by layers, the aqueous phase was extracted with 100ml*2 ethyl acetate, the combined organic phases were washed with 50ml of saturated brine, dried by adding 20g of anhydrous sodium sulfate, and filtered. The salt was removed, and the solvent was removed by concentration; 10.7 g of intermediate 1 was obtained by column chromatography (pure EA), the yield was 79.9%, and the HPLC purity was 94%.

实施例3Example 3

在500ml三口瓶中,加入10.0g(0.034mol)化合物I,加300ml乙腈;加入18.7g(0.136mol) 碳酸钾,体系呈浑浊白色,升温到50-55℃,分批加入23.4g(0.136mol)N,N-二乙基-β-氯乙胺 盐酸盐,过程中体系渐溶清。升温到80-85℃反应2小时。TLC检测反应完全,反应液降温, 加入50ml水,分层分出有机相,水相加100ml*2乙酸乙酯萃取,合并有机相加50ml饱和食 盐水洗涤,加入20g无水硫酸钠干燥,过滤除去盐,浓缩除去溶剂;经柱层析(纯EA)得到 10.2g中间体1,收率76.1%,HPLC纯度90%。In a 500ml three-necked flask, add 10.0g (0.034mol) of compound I, add 300ml of acetonitrile; add 18.7g (0.136mol) of potassium carbonate, the system is cloudy white, warm up to 50-55°C, add 23.4g (0.136mol) in batches ) N,N-diethyl-β-chloroethylamine hydrochloride, the system gradually dissolves and clears during the process. The temperature was raised to 80-85°C for 2 hours. TLC detected that the reaction was complete, the reaction solution was cooled, 50ml of water was added, the organic phase was separated by layers, the aqueous phase was extracted with 100ml*2 ethyl acetate, the combined organic phases were washed with 50ml of saturated brine, dried by adding 20g of anhydrous sodium sulfate, and filtered. The salt was removed, and the solvent was removed by concentration; 10.2 g of intermediate 1 was obtained by column chromatography (pure EA), the yield was 76.1%, and the HPLC purity was 90%.

实施例4Example 4

在500ml三口瓶中,加入230ml甲醇,加入11.5g(0.029mol)中间体1,冰浴降温到0-5℃ 加入1.2g(0.029mol)氢氧化钠。保持温度0-5℃,分10批次加入6.6g(0.026mol)单质碘。 加完后保温反应6小时,HPLC检测反应显示原料剩余15%,单碘目标产物占比75%,二碘 副产物占比10%。体系中加入200ml水搅拌10分钟,低温浓缩除去大部分甲醇溶剂,加入200ml*2乙酸乙酯萃取,分层合并有机相加入50ml饱和食盐水洗涤有机相,分层有机相加入20g无水硫酸钠干燥抽滤,滤液浓缩至干,经柱层析(纯EA)得到粗品12.3g,用60ml乙腈 重结晶得到10.2g,加入100ml甲醇溶解,滴加盐酸甲醇调节PH到6,有大量白色固体析出, 搅拌0.5小时,抽滤,滤饼加少量甲醇淋洗,抽干得到9.4g目标产物,产率62.7%,HPLC 纯度98%。In a 500ml three-necked flask, add 230ml of methanol, add 11.5g (0.029mol) of intermediate 1, cool down to 0-5°C in an ice bath, and add 1.2g (0.029mol) of sodium hydroxide. Keeping the temperature at 0-5° C., 6.6 g (0.026 mol) of elemental iodine was added in 10 batches. After adding, the reaction was incubated for 6 hours, and the HPLC detection reaction showed that the remaining 15% of the raw material, the mono-iodine target product accounted for 75%, and the diiodine by-product accounted for 10%. Add 200ml of water to the system and stir for 10 minutes, concentrate at low temperature to remove most of the methanol solvent, add 200ml*2 of ethyl acetate for extraction, combine the organic phases by layering, add 50ml of saturated brine to wash the organic phase, add 20g of anhydrous sodium sulfate to the layered organic phase Dry and suction filter, concentrate the filtrate to dryness, obtain 12.3 g of crude product through column chromatography (pure EA), recrystallize with 60 ml of acetonitrile to obtain 10.2 g, add 100 ml of methanol to dissolve, dropwise add hydrochloric acid methanol to adjust the pH to 6, and a large amount of white solids are precipitated , stirred for 0.5 hours, suction filtered, the filter cake was rinsed with a small amount of methanol, and dried to obtain 9.4 g of the target product, the yield was 62.7%, and the HPLC purity was 98%.

实施例5Example 5

在500ml三口瓶中,加入230ml甲醇,加入11.5g(0.029mol)中间体1,冰浴降温到5-10℃, 加入8.0g(0.058mol)碳酸钾。保持温度5-10℃,分10批次加入7.4g(0.029mol)单质碘。 加完后保温反应12小时,HPLC检测反应显示原料剩余6%,单碘目标产物占比70%,二碘 副产物占比20%。体系中加入200ml水搅拌10分钟,低温浓缩除去大部分甲醇溶剂,加入200ml*2乙酸乙酯萃取,分层合并有机相加入50ml饱和食盐水洗涤有机相,分层有机相加入20g无水硫酸钠干燥抽滤,滤液浓缩至干,经柱层析(纯EA)得到粗品10.6g,用60ml乙腈 重结晶得到9.1g,加入100ml甲醇溶解,滴加盐酸甲醇调节PH到6,有大量白色固体析出, 搅拌0.5小时,抽滤,滤饼加少量甲醇淋洗,抽干得到8.6g目标产物,产率57.3%,HPLC 纯度87%。In a 500ml three-necked flask, add 230ml of methanol, add 11.5g (0.029mol) of intermediate 1, cool down to 5-10°C in an ice bath, and add 8.0g (0.058mol) of potassium carbonate. Keeping the temperature at 5-10° C., 7.4 g (0.029 mol) of elemental iodine was added in 10 batches. After adding, the reaction was incubated for 12 hours, and the HPLC detection reaction showed that the remaining 6% of the raw material, the mono-iodine target product accounted for 70%, and the diiodine by-product accounted for 20%. Add 200ml of water to the system and stir for 10 minutes, concentrate at low temperature to remove most of the methanol solvent, add 200ml*2 of ethyl acetate for extraction, combine the organic phases by layering, add 50ml of saturated brine to wash the organic phase, add 20g of anhydrous sodium sulfate to the layered organic phase Dry and suction filter, concentrate the filtrate to dryness, obtain 10.6g of crude product by column chromatography (pure EA), recrystallize with 60ml of acetonitrile to obtain 9.1g, add 100ml of methanol to dissolve, dropwise add hydrochloric acid methanol to adjust the pH to 6, and a large amount of white solids are precipitated , stirred for 0.5 hours, suction filtered, the filter cake was rinsed with a small amount of methanol, and dried to obtain 8.6 g of the target product, the yield was 57.3%, and the HPLC purity was 87%.

实施例6Example 6

在500ml三口瓶中,加入230ml甲醇,加入11.5g(0.029mol)中间体1,冰浴降温到5-10℃, 加入2.8g(0.116mol)氢氧化锂。保持温度5-10℃,分10批次加入6.6g(0.026mol)单质碘。 加完后保温反应6小时,HPLC检测反应显示原料剩余30%,单碘目标产物占比60%,二碘 副产物占比10%。体系中加入200ml水搅拌10分钟,低温浓缩除去大部分甲醇溶剂,加入 200ml*2乙酸乙酯萃取,分层合并有机相加入50ml饱和食盐水洗涤有机相,分层有机相加入 20g无水硫酸钠干燥抽滤,滤液浓缩至干,经柱层析(纯EA)得到粗品10.3g,用60ml乙腈 重结晶得到8.3g,加入100ml甲醇溶解,滴加盐酸甲醇调节PH到6,有大量白色固体析出,搅拌0.5小时,抽滤,滤饼加少量甲醇淋洗,抽干得到8.1g目标产物,产率54.0%,HPLC 纯度91%。In a 500ml three-necked flask, add 230ml of methanol, add 11.5g (0.029mol) of intermediate 1, cool down to 5-10°C in an ice bath, and add 2.8g (0.116mol) of lithium hydroxide. Keeping the temperature at 5-10° C., 6.6 g (0.026 mol) of elemental iodine was added in 10 batches. After adding, the reaction was incubated for 6 hours, and the HPLC detection reaction showed that the remaining 30% of the raw material, the mono-iodine target product accounted for 60%, and the diiodine by-product accounted for 10%. Add 200ml of water to the system and stir for 10 minutes, concentrate at low temperature to remove most of the methanol solvent, add 200ml*2 of ethyl acetate for extraction, combine the organic phases by layering, add 50ml of saturated brine to wash the organic phase, add 20g of anhydrous sodium sulfate to the layered organic phase Dry and suction filter, concentrate the filtrate to dryness, obtain 10.3 g of crude product through column chromatography (pure EA), recrystallize with 60 ml of acetonitrile to obtain 8.3 g, add 100 ml of methanol to dissolve, dropwise add hydrochloric acid methanol to adjust the pH to 6, and a large amount of white solids are precipitated , stirred for 0.5 hours, suction filtered, the filter cake was rinsed with a small amount of methanol, and dried to obtain 8.1 g of the target product, the yield was 54.0%, and the HPLC purity was 91%.

需要说明的是,以上内容仅仅说明了本发明的技术思想,不能以此限定本发明的保护范 围,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干 改进和润饰,这些改进和润饰均落入本发明权利要求书的保护范围之内。It should be noted that the above content only illustrates the technical idea of the present invention, and cannot limit the protection scope of the present invention. Several improvements and modifications can be made, which all fall within the protection scope of the claims of the present invention.

Claims (9)

1.一种胺碘酮杂质C的合成方法,其特征在于,包括以下步骤:1. a synthetic method of amiodarone impurity C, is characterized in that, comprises the following steps: (1)将化合物Ⅰ溶于溶剂中,在碱的作用下,与N,N-二乙基-β-氯乙胺盐酸盐进行取代反应得到中间体1;(1) dissolving compound I in a solvent, and under the action of a base, carry out a substitution reaction with N,N-diethyl-β-chloroethylamine hydrochloride to obtain intermediate 1;
Figure FDA0003446769710000011
Figure FDA0003446769710000011
(2)中间体1溶于溶剂中,在碱的作用下,与碘单质反应得到胺碘酮杂质C;(2) Intermediate 1 is dissolved in a solvent, and under the action of alkali, reacts with elemental iodine to obtain amiodarone impurity C;
Figure FDA0003446769710000012
Figure FDA0003446769710000012
2.根据权利要求1所述的一种胺碘酮杂质C的合成方法,其特征在于,步骤(1)中,所述化合物Ⅰ与N,N-二乙基-β-氯乙胺盐酸盐的摩尔比为1:1.0-4.0。2. the synthetic method of a kind of amiodarone impurity C according to claim 1, is characterized in that, in step (1), described compound I and N,N-diethyl-β-chloroethylamine hydrochloride The molar ratio of the salt is 1:1.0-4.0. 3.根据权利要求1所述的一种胺碘酮杂质C的合成方法,其特征在于,步骤(1)中,所述碱与化合物I的摩尔比为1.0-4.0:1.0;所述溶剂与化合物I的体积比为1.0-100:1.0。3. the synthetic method of a kind of amiodarone impurity C according to claim 1, is characterized in that, in step (1), the mol ratio of described base and compound I is 1.0-4.0:1.0; The volume ratio of compound I is 1.0-100:1.0. 4.根据权利要求1所述的一种胺碘酮杂质C的合成方法,其特征在于,步骤(1)中,所述碱为碳酸钾、碳酸钠、碳酸铯、氢氧化钠、氢氧化钾、氢氧化锂中的一种或多种;所述溶剂为甲苯、水、乙腈、丙酮、四氢呋喃、N,N-二甲基甲酰胺、二甲基亚砜中的一种或多种。4. the synthetic method of a kind of amiodarone impurity C according to claim 1, is characterized in that, in step (1), described alkali is potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide , one or more of lithium hydroxide; the solvent is one or more of toluene, water, acetonitrile, acetone, tetrahydrofuran, N,N-dimethylformamide and dimethyl sulfoxide. 5.根据权利要求1所述的一种胺碘酮杂质C的合成方法,其特征在于,步骤(1)中,所述取代反应的温度为30-90℃,反应的时间为1-6小时。5. the synthetic method of a kind of amiodarone impurity C according to claim 1, is characterized in that, in step (1), the temperature of described substitution reaction is 30-90 ℃, and the time of reaction is 1-6 hour . 6.根据权利要求1所述的一种胺碘酮杂质C的合成方法,其特征在于,步骤(2)中,所述间体1与碘单质的摩尔比为1:0.5-5.0。6. the synthetic method of a kind of amiodarone impurity C according to claim 1, is characterized in that, in step (2), the mol ratio of described intermediate 1 and iodine elemental substance is 1:0.5-5.0. 7.根据权利要求1所述的一种胺碘酮EP杂质的合成方法,其特征在于,步骤(2)中,所述碱与中间体1的摩尔比为1.0-5.0:1.0;所述溶剂与中间体1的体积比为1.0-100:1.0。7. the synthetic method of a kind of amiodarone EP impurity according to claim 1, is characterized in that, in step (2), the mol ratio of described alkali and intermediate 1 is 1.0-5.0:1.0; Described solvent The volume ratio to Intermediate 1 is 1.0-100:1.0. 8.根据权利要求1所述的一种胺碘酮杂质C的合成方法,其特征在于,步骤(2)中,所述碱为碳酸钾、碳酸钠、碳酸铯、氢氧化钠、氢氧化钾、氢氧化锂中的一种或多种;所述溶剂为甲醇、乙醇、异丙醇、丙酮、乙腈、四氢呋喃、乙酸乙酯中的一种或多种。8. the synthetic method of a kind of amiodarone impurity C according to claim 1, is characterized in that, in step (2), described alkali is potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide , one or more of lithium hydroxide; the solvent is one or more of methanol, ethanol, isopropanol, acetone, acetonitrile, tetrahydrofuran, and ethyl acetate. 9.根据权利要求1所述的一种胺碘酮杂质C的合成方法,其特征在于,步骤(2)中,所述反应的温度为0-30℃,反应的时间为2-12小时。9. the synthetic method of a kind of amiodarone impurity C according to claim 1, is characterized in that, in step (2), the temperature of described reaction is 0-30 ℃, and the time of reaction is 2-12 hours.
CN202111660207.8A 2021-12-30 2021-12-30 A synthetic method for amiodarone impurity C Active CN114671836B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111660207.8A CN114671836B (en) 2021-12-30 2021-12-30 A synthetic method for amiodarone impurity C

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111660207.8A CN114671836B (en) 2021-12-30 2021-12-30 A synthetic method for amiodarone impurity C

Publications (2)

Publication Number Publication Date
CN114671836A true CN114671836A (en) 2022-06-28
CN114671836B CN114671836B (en) 2025-04-18

Family

ID=82069897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111660207.8A Active CN114671836B (en) 2021-12-30 2021-12-30 A synthetic method for amiodarone impurity C

Country Status (1)

Country Link
CN (1) CN114671836B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575513A (en) * 1983-08-02 1986-03-11 Sanofi Pharmaceutical and veterinary compositions for the treatment of ischemic cardiac disorders
CN109053652A (en) * 2018-09-04 2018-12-21 北京深蓝海生物医药科技有限公司 A kind of preparation method of Amiodarone Hydrochloride intermediate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575513A (en) * 1983-08-02 1986-03-11 Sanofi Pharmaceutical and veterinary compositions for the treatment of ischemic cardiac disorders
CN109053652A (en) * 2018-09-04 2018-12-21 北京深蓝海生物医药科技有限公司 A kind of preparation method of Amiodarone Hydrochloride intermediate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AARON N. SNEAD ET AL.: "Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 18, 9 August 2008 (2008-08-09), pages 5920 - 5922, XP025627170, DOI: 10.1016/j.bmcl.2008.08.013 *
NICOLAS FAUCHER ET AL.: "Highly Chemoselective Hydrogenolysis of Iodoarenes", 《JOURNAL OF ORGANIC CHEMISTRY》, vol. 67, 15 January 2002 (2002-01-15), pages 932 - 934 *
NICOLAS FAUCHER ET AL.: "Highly Chemoselective Hydrogenolysis of Iodoarenes", JOURNAL OF ORGANIC CHEMISTRY, vol. 67, 15 January 2002 (2002-01-15), pages 932 - 934 *

Also Published As

Publication number Publication date
CN114671836B (en) 2025-04-18

Similar Documents

Publication Publication Date Title
CN109988132B (en) Preparation method of amiodarone hydrochloride
WO2023060811A1 (en) Fluralaner intermediate and method for preparing fluralaner thereby
CN112079848A (en) Synthesis method of baroxavir key intermediate
TWI703163B (en) Method for preparing sugammadex sodium and crystalline form thereof
CN118754880A (en) A method for preparing a cyclopropyl-substituted 2H-benzofuran compound intermediate
CN102351778A (en) Preparation method of arbidol hydrochloride
CN100408588C (en) Oxaliplatin with low content of associated impurities and preparation method thereof
WO2005023753A1 (en) A method of preparing memantine hydrochloride
CN114671836A (en) A kind of synthetic method of amiodarone impurity C
KR20040043171A (en) Novel modifications of the trometamol salt of R-thioctic acid and method for producing the same
CN116425729A (en) Litaset morpholine salt and preparation method and application thereof
CN113072514B (en) Preparation method of Xuanjinning and intermediate thereof
CN115872906A (en) Levatinib impurity and preparation method thereof
CN104530055A (en) Preparation method of tofacitinib citrate
CN100503567C (en) The preparation method of 4-bromo-7-methyl isatin
CN111320547B (en) Synthesis method of lumefantrine-D9
CN113956198A (en) Impurity of roxasistat, preparation method and application thereof
CN109553649B (en) A kind of preparation method of canagliflozin intermediate
CN118561739A (en) Preparation method of 5-aminolevulinic acid hydrochloride intermediate
CN111808156A (en) Beta-nicotinamide riboside chloride crystal form 1A and crystal form 1B and preparation method thereof
CN111662260B (en) A kind of synthetic method of natural product saffloneoside
CN114369032B (en) A method for synthesizing important impurities of bisoprolol
WO2023103306A1 (en) Method for preparing deuterated cytidine derivative
CN116514896B (en) A method for synthesizing dihydrotanshinone I
KR100829894B1 (en) Method for preparing dimacrotic acid and its magnesium salt

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant